Are We Ready For “Triplet” Therapy in Higher-Risk MDS?

Higher-risk Myelodysplastic Syndromes/Neoplasms (MDS) represent an ongoing therapeutic challenge, with few effective therapies, many of which may have limited use in this older patient population often with considerations around comorbidities. Outside of transplant, azacitidine and decitabine remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunner, Andrew M., Platzbecker, Uwe, DeZern, Amy E., Zeidan, Amer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Academy for Clinical Hematology (IACH) 2023
Materias:
Perspective Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625655/
https://www.ncbi.nlm.nih.gov/pubmed/37933301
http://dx.doi.org/10.46989/001c.88301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625655/
https://www.ncbi.nlm.nih.gov/pubmed/37933301
http://dx.doi.org/10.46989/001c.88301

Ejemplares similares